Results 151 to 160 of about 17,431 (301)

Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. [PDF]

, 2016
Oncolytic reovirus can be delivered both systemically and intratumorally, in both pre-clinical models and in early phase clinical trials. Reovirus has direct oncolytic activity against a variety of tumor types and anti-tumor activity is directly ...
Coffey, M, Diaz, RM, Harrington, K, Ilett, E, Kottke, T, Melcher, A, Pandha, H, Parrish, C, Rajani, K, Shim, KG, Thompson, J, Vile, R, Zaidi, S   +12 more
core   +1 more source

Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression

OncoImmunology, 2019
Antitumor cytotoxic T lymphocytes (CTLs) are essential for immune surveillance, yet the blockade of eliciting such CTLs during oncolytic virotherapy remains incompletely understood.
Zhiwu Tan, Li Liu, Mei Sum Chiu, Ka-Wai Cheung, Chi Wing Yan, Zhe Yu, Boon Kiat Lee, Wan Liu, Kwan Man, Zhiwei Chen   +9 more
doaj   +1 more source

The essential role of mitochondrial dynamics in antiviral immunity. [PDF]

, 2018
Viruses alter cellular physiology and function to establish cellular environment conducive for viral proliferation. Viral immune evasion is an essential aspect of viral persistence and proliferation.
Ahn, Dae-Gyun, Kim, Seong-Jun, Siddiqui, Aleem, Syed, Gulam H   +3 more
core   +2 more sources

The combination therapy of oncolytic virotherapy

Frontiers in Pharmacology
Introduction: Compared to other cancer immunotherapies, oncolytic viruses possess several advantages, including high killing efficiency, excellent targeting capabilities, minimal adverse reactions, and multiple pathways for tumor destruction. However, the efficacy of oncolytic viruses as a monotherapy often falls short of expectations.
Yue Wang, Mengying Zhu, Mengying Zhu, Huanyu Chi, Huanyu Chi, Yang Liu, Guilin Yu   +6 more
openaire   +3 more sources

Editorial: Oncolytic virotherapy

Frontiers in Molecular Biosciences, 2023
Ahmed Majeed Al-Shammari, Pier Paolo Piccaluga, Pier Paolo Piccaluga   +2 more
openaire   +3 more sources

Reverse genetics of Mononegavirales: How they work, new vaccines, and new cancer therapeutics. [PDF]

, 2015
The order Mononegavirales includes five families: Bornaviridae, Filoviridae, Nyamaviridae, Paramyxoviridae, and Rhabdoviridae. The genome of these viruses is one molecule of negative-sense single strand RNA coding for five to ten genes in a conserved ...
Cattaneo, Roberto, Pfaller, Christian K, Schnell, Matthias J.   +2 more
core   +2 more sources

Virotherapy clinical trials for regional disease: In situ immune modulation using recombinant poxvirus vectors [PDF]

, 2002
Michael J. Mastrangelo, Edmund C. Lattime   +1 more
openalex   +1 more source

Oncolytic Viruses for Cancer Therapy: Barriers and Recent Advances

Molecular Therapy: Oncolytics, 2019
Oncolytic viruses (OVs) are powerful new therapeutic agents in cancer therapy. With the first OV (talimogene laherparepvec [T-vec]) obtaining US Food and Drug Administration approval, interest in OVs has been boosted greatly.
Meijun Zheng, Jianhan Huang, Aiping Tong, Hui Yang   +3 more
doaj  

Virotherapy for cancer: Current status, hurdles, and future directions [PDF]

, 2002
David H. Kirn
openalex   +1 more source

Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial

Nature Network Boston, 2023
H. Soliman, D. Hogue, H. Han, Blaise Mooney, R. Costa, Marie Catherine Lee, B. Niell, Angela Williams, A. Chau, Shannon Falcon, A. Soyano, Avan J Armaghani, N. Khakpour, R. Weinfurtner, S. Hoover, J. Kiluk, C. Laronga, M. Rosa, H. Khong, B. Czerniecki   +19 more
semanticscholar   +1 more source